111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Achieved First-Ever Annual Operating Profit Bottom Line Improved by RMB332.7 Million YoY in 2024 Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoY Achieved First-Ever Annual Positive Operating Cash Flow SHANGHAI, March 20, 2025 /PRNewswire/ -- 111,...
BenQ Medical Technology and Brain Navi Align Partnership to Advance Neurosurgical Robotics in China
Enhancing Precision and Innovation in Neurosurgical Robotics Across China ZHUBEI, March 20, 2025 /PRNewswire/ -- Brain Navi Biotechnology, a leading innovator in neurosurgical robotics, has announced a strategic partnership with BenQ Medical Technology to introduce and commercialize the NaoTrac neurosurgical navigation robot in the Chinese market. This collaboration aligns with Brain Navi's 2025...
HiRO and Hallym University Sacred Heart Hospital Sign Strategic MOU to Advance Drug Development
SEOUL, South Korea, March 20, 2025 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a boutique global CRO, is pleased to announce the signing of a Memorandum of Understanding (MOU) with Hallym University Sacred Heart Hospital in Seoul, South Korea. This strategic alliance aims to drive innovation in drug research and development while...
Medit Partners with Imagoworks to Enhance Edentulous Prosthetic Workflow
By integrating Medit SmartX with Imagoworks' AOX, dental professionals can streamline the edentulous prosthetic workflow, ensuring seamless data transfer, precise prosthetic design, and enhanced restoration services for improved patient care. SEOUL, South Korea, March 20, 2025 /PRNewswire/ -- Medit, a leading provider of dental 3D intraoral scanners and digital dentistry solutions, and Imagoworks, specializing...
Pearl Partners with Medit to Enhance AI-Powered Dental Diagnostics in Intraoral Scanning and Medit Link Software Platform
By integrating Pearl's AI-powered diagnostic solutions with Medit Link, dental clinicians will gain access to advanced diagnostic support and enhanced communication tools that would improve clinical outcomes and patient experiences SEOUL, South Korea and LOS ANGELES, March 20, 2025 /PRNewswire/ -- Medit, a leading provider of dental 3D intraoral scanners and digital dentistry solutions,...
HAVAS UNVEILS “NEUROVERSE” TO UNLOCK UNTAPPED MARKET POTENTIAL THROUGH NEURODIVERSITY
1 in 5 People Are Neurodivergent¹—Brands That Engage This Growing, Influential Community Tap Into $1.9 Trillion in Annual Disposable Income Globally.² NEW YORK, March 20, 2025 /PRNewswire/ -- Havas today announces the launch of Neuroverse: Powered by Havas — its new Neurodiversity Center of Excellence (CoE), a groundbreaking consultancy dedicated to embedding neurodivergent talent into the heart of its creative marketing,...
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer. Receiving an Orphan Drug Designation for HLX22 recognizes its potential to treat patients with gastric cancer and marks another milestone for HLX22,...
SI Group Awarded Bronze Medal by EcoVadis for Corporate Social Responsibility
Company Ranked in the Top 35% of All Rated Companies Underscoring the Company's Commitment to Good Sustainability Practices THE WOODLANDS, Texas, March 19, 2025 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, has received a Bronze medal from EcoVadis, a globally...
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development
CRANBURY, N.J., March 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies. Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate...
Alamar Biosciences Announces First Five Distribution Partners, Expanding Commercial Support in Asia Pacific
FREMONT, Calif., March 19, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new distribution partners to expand its global presence. The company has partnered with established industry leaders across key international markets to enhance access to its innovative proteomics technologies. ...
